Compared to the STING protein, cGAS has been relatively underappreciated as a druggable target for cancer immunotherapy (31), despite the potential of a cGAS-targeting therapeutic to more closely mimic endogenous STING signaling by simulating natural, endogenous DNA sensing. The gene discussed is STING1; the disease is cancer.